Data as of Apr 17
| -0.22 / -1.55%|
The 11 analysts offering 12-month price forecasts for ImmunoGen Inc have a median target of 18.00, with a high estimate of 24.00 and a low estimate of 8.50. The median estimate represents a +28.66% increase from the last price of 13.99.
The current consensus among 14 polled investment analysts is to Buy stock in ImmunoGen Inc. This rating has held steady since April, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.